Atlas FDA

Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote Management

FDA premarket approval P210037 · decided 2023-03-31

Approval details

PMA number
P210037
Trade name
Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote Management
Generic name
Stimulator, spinal-cord, totally implanted for pain relief
Applicant
Biotronik Nro, Inc.
Date received
2021-12-02
Decision date
2023-03-31
Days to decision
484 days
Decision code
APPR
Product code
LGW
Advisory committee
Neurology
Expedited review
No
Location
Lake Oswego, OR
Statement
Approval for the Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote Management. The Indications for Use (IFU) of the device is as follows:The Prospera spinal cord stimulation (SCS) system is indicated as an aid in the management of chronic, intractable pain in the trunk and/or limbs, which may include unilateral or bilateral pain, resulting from any of the following: 1) Failed Back Syndrome (FBS) or low back syndrome or failed back; 2) Radicular pain s

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.